A Pilot Trial of Triheptanoin for the Preventive Treatment of Migraine

A Pilot Trial of Triheptanoin for the Preventive Treatment of Migraine

A pilot trial of triheptanoin, a natural compound able to promote anaplerotic mitochondrial metabolism, for the preventative treatment of migraine.

To test the ability of a daily 3-month treatment with triheptanoin to prevent migraine attacks in 10 migraine patients.

This is an open, non-randomized pilot trial that might justify a placebo-controlled trial, if there are at least 50% of patients with ≥50% reduction in attack frequency.

Inclusion Criteria:

• Females aged 18-65 years old having an effective contraception or being menopaused
• Diagnosis of migraine without aura (ICHD3beta 1.1) since at least 2 years
• 4-10 migraine days per month during the last 3 months
• No preventive anti-migraine therapy during the last month

Exclusion Criteria:

• > 4 tension-type headache episodes per month
• Medication overuse headache or other headache types
• Resistance to >3 previous preventive anti-migraine drug treatments
• Any serious medical or psychiatric condition
• On-going or previous bowel disorder